Raw & starting materials quality, sourcing and management 2022

Innovating in iPSC differentiation & engineering

Cell & Gene Therapy Insights 2022; 8(10), 1437–1443

DOI: 10.18609/cgti.2022.209

Published: 30 November 2022
Emily Titus

Emily Titus obtained her PhD from the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, where she used a combination of laboratory and bioinformatics approaches to define and interpret gene regulatory networks controlling embryonic stem cell fate decisions. At Notch, she oversees the Technical Operations function, which includes Process and Analytical Development, Manufacturing Sciences, Engineering and Project Management. Previously, she held the position of Vice President, Technology Advancement at CCRM, where she built cell reprogramming, genome engineering and pluripotent stem cell differentiation programs and led the company incubation program that culminated in the launch of Notch Therapeutics.

David McCall, Commissioning Editor, BioInsights, speaks to Emily Titus, Senior Vice President, Technical Operations, Notch Therapeutics